Jefferies Weighs In on Ultragenyx Pharma (RARE) Related to SIMD Abstracts
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Ultragenyx Pharma (RARE) Tops Q4 EPS by 1c
March 25, 2015 4:06 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($0.52), $0.01 better than the analyst estimate of ($0.53).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
... MoreCRT Capital Starts Ultragenyx Pharma (RARE) at Buy
March 24, 2015 4:29 PM EDTCRT Capital initiated coverage on Ultragenyx Pharma (NASDAQ: RARE) with a Buy rating and a price target of $90.00.
For an analyst ratings summary and ratings history on Ultragenyx Pharma click here. For more ratings news on Ultragenyx Pharma click here.
Shares of Ultragenyx Pharma closed at $59.96 yesterday.
... More